SUPN · Nasdaq · Healthcare · Drug Manufacturers Specialty and Generic
$29.72+1.8%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed October 29, 2026
Just reported
From Supernus Pharmaceuticals, Inc.'s results release of October 29, 2026; its quarterly report has since been filed.
Actual
$226.8M
+18% y/y
+3.5% q/q
Guided
—
No guide given
Actual
$0.35
Guided
—
No guide given
Actual
$21.2M
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $226.8M | $192.1M | +18.05% |
| Profit | $20.9M | -$45.1M | +146.35% |
| Profit per share | $0.35 | -$0.80 | +143.75% |
| Free Cash Flow | $6.4M | -$61.8M | +110.32% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Supernus Pharmaceuticals, Inc. has no earnings call transcript available.
“Our strong operating execution year-to-date delivered total revenue growth of 29%, which shows the continued momentum across our commercial portfolio, specifically our growth products.”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Our diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. We are developing a broad range of novel product candidates for CNS disorders.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Supernus Pharmaceuticals, Inc.’s Item 2.02 8-K filed October 29, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.